Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Scathing TAVR critique from Belgium; arrest of top CDRH official; more device industry news.

You may also be interested in...



Radiation Oncologists Question Double-Digit Cuts To Medicare Physician Payments

In its draft 2013 physician fee schedule issued July 6, CMS proposes an overall 14% decrease in reimbursement rates for radiation oncology therapy services based on new assumptions for intensity modulated radiation therapy and stereotactic body radiation therapy procedure times.

Covidien Aims To Double Sales In Emerging Markets By 2017

Covidien plans to double its sales in emerging markets, primarily China and India, to $2 billion over the next five to six years, CEO Jose E. Almeida said during the firm’s Sept. 8 investor meeting in New York.

Personal Care Next Target For UK Competition Authority ‘Greenwashing’ Audit

Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel